Re: Risk of Recurrent Disease in HER2-Positive Patients
This GUN study is a real eye-opener for me. I will have to take it up with my doctor soon. One thing I believe I am seeing in figure 5. of the report is that for at least the first year to year and a half there does not appear to be any significance in the OS of the Her2+/ER+ with TAM group versus those not taking TAM. Hopefully, that should allow me enough time to work out the pros and cons of switching to an AI or finding a way to continue the Her2 blockade once my Herceptin year ends in July.
This hormonal therapy is so complicated. Out of all the therapies I have had to deal with since diagnosis last year, it has been the hardest by far for me to deal with.
bird
__________________
Male Breast Cancer, DX 5/15/09, IDC, STAGE 1, 1.7 cm, HER2+++, ER+(95%)/PR+(75%), Ki67 40%, grade 3, 0/5 nodes, TX: mastectomy, TCH finished 7/19/10, radiation 6 wks., Tamoxifen on going, bisphosphonate 24 mos.
|